Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history

A multi-institutional study

Keiichi Jingu, Yuzuru Niibe, Hideomi Yamashita, Kuniaki Katsui, Toshihiko Matsumoto, Tomohiro Nishina, Atsuro Terahara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Neoadjuvant chemoradiotherapy following surgery has recently become a standard therapy. The purpose of the present study was to determine the effectiveness and toxicity of re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy. Methods: We reviewed retrospectively 248 patients treated with (chemo)radiotherapy for oligo-recurrence in lymph nodes from esophageal cancer in five Japanese high-volume centers between 2000 and 2015. Thirty-three patients in whom re-irradiation was performed were enrolled in this study, and the results for patients in whom re-irradiation was performed were compared with the results for other patients. Results: Median maximum lymph node diameter was 22 mm. Median total radiation dose was 60 Gy. The median calculated biological effective dose using the LQ model with α/β = 10 Gy (BED10) in patients in whom re-irradiation was performed was significantly lower than the median BED10 in others. There was no different factor except for BED10, histology and irradiation field between patients with a past irradiation history and patients without a past irradiation history. The median observation period in surviving patients in whom re-irradiation was performed was 21.7 months. The 3-year overall survival rate in the 33 patients with a past irradiation history was 17.9%, with a median survival period of 16.0 months. Overall survival rate and local control rate in patients with a past irradiation history were significantly worse than those in patients without a past irradiation history (log-rank test, p = 0.016 and p = 0.0007, respectively). One patient in whom re-irradiation was performed died from treatment-related gastric hemorrhage. Conclusions: Results in the present study suggested that re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy might be acceptable but unsatisfactory.

Original languageEnglish
Article number146
JournalRadiation Oncology
Volume12
Issue number1
DOIs
Publication statusPublished - Sep 5 2017

Fingerprint

Esophageal Neoplasms
Radiotherapy
History
Recurrence
Lymph Nodes
Re-Irradiation
Survival Rate
Chemoradiotherapy
Stomach
Histology
Observation
Radiation
Hemorrhage

Keywords

  • Chemoradiotherapy
  • Esophageal cancer
  • Oligo-recurrence
  • Re-irradiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history : A multi-institutional study. / Jingu, Keiichi; Niibe, Yuzuru; Yamashita, Hideomi; Katsui, Kuniaki; Matsumoto, Toshihiko; Nishina, Tomohiro; Terahara, Atsuro.

In: Radiation Oncology, Vol. 12, No. 1, 146, 05.09.2017.

Research output: Contribution to journalArticle

Jingu, Keiichi ; Niibe, Yuzuru ; Yamashita, Hideomi ; Katsui, Kuniaki ; Matsumoto, Toshihiko ; Nishina, Tomohiro ; Terahara, Atsuro. / Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history : A multi-institutional study. In: Radiation Oncology. 2017 ; Vol. 12, No. 1.
@article{c8910a759acf44d98a02efa8b4613427,
title = "Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: A multi-institutional study",
abstract = "Background: Neoadjuvant chemoradiotherapy following surgery has recently become a standard therapy. The purpose of the present study was to determine the effectiveness and toxicity of re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy. Methods: We reviewed retrospectively 248 patients treated with (chemo)radiotherapy for oligo-recurrence in lymph nodes from esophageal cancer in five Japanese high-volume centers between 2000 and 2015. Thirty-three patients in whom re-irradiation was performed were enrolled in this study, and the results for patients in whom re-irradiation was performed were compared with the results for other patients. Results: Median maximum lymph node diameter was 22 mm. Median total radiation dose was 60 Gy. The median calculated biological effective dose using the LQ model with α/β = 10 Gy (BED10) in patients in whom re-irradiation was performed was significantly lower than the median BED10 in others. There was no different factor except for BED10, histology and irradiation field between patients with a past irradiation history and patients without a past irradiation history. The median observation period in surviving patients in whom re-irradiation was performed was 21.7 months. The 3-year overall survival rate in the 33 patients with a past irradiation history was 17.9{\%}, with a median survival period of 16.0 months. Overall survival rate and local control rate in patients with a past irradiation history were significantly worse than those in patients without a past irradiation history (log-rank test, p = 0.016 and p = 0.0007, respectively). One patient in whom re-irradiation was performed died from treatment-related gastric hemorrhage. Conclusions: Results in the present study suggested that re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy might be acceptable but unsatisfactory.",
keywords = "Chemoradiotherapy, Esophageal cancer, Oligo-recurrence, Re-irradiation",
author = "Keiichi Jingu and Yuzuru Niibe and Hideomi Yamashita and Kuniaki Katsui and Toshihiko Matsumoto and Tomohiro Nishina and Atsuro Terahara",
year = "2017",
month = "9",
day = "5",
doi = "10.1186/s13014-017-0882-0",
language = "English",
volume = "12",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history

T2 - A multi-institutional study

AU - Jingu, Keiichi

AU - Niibe, Yuzuru

AU - Yamashita, Hideomi

AU - Katsui, Kuniaki

AU - Matsumoto, Toshihiko

AU - Nishina, Tomohiro

AU - Terahara, Atsuro

PY - 2017/9/5

Y1 - 2017/9/5

N2 - Background: Neoadjuvant chemoradiotherapy following surgery has recently become a standard therapy. The purpose of the present study was to determine the effectiveness and toxicity of re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy. Methods: We reviewed retrospectively 248 patients treated with (chemo)radiotherapy for oligo-recurrence in lymph nodes from esophageal cancer in five Japanese high-volume centers between 2000 and 2015. Thirty-three patients in whom re-irradiation was performed were enrolled in this study, and the results for patients in whom re-irradiation was performed were compared with the results for other patients. Results: Median maximum lymph node diameter was 22 mm. Median total radiation dose was 60 Gy. The median calculated biological effective dose using the LQ model with α/β = 10 Gy (BED10) in patients in whom re-irradiation was performed was significantly lower than the median BED10 in others. There was no different factor except for BED10, histology and irradiation field between patients with a past irradiation history and patients without a past irradiation history. The median observation period in surviving patients in whom re-irradiation was performed was 21.7 months. The 3-year overall survival rate in the 33 patients with a past irradiation history was 17.9%, with a median survival period of 16.0 months. Overall survival rate and local control rate in patients with a past irradiation history were significantly worse than those in patients without a past irradiation history (log-rank test, p = 0.016 and p = 0.0007, respectively). One patient in whom re-irradiation was performed died from treatment-related gastric hemorrhage. Conclusions: Results in the present study suggested that re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy might be acceptable but unsatisfactory.

AB - Background: Neoadjuvant chemoradiotherapy following surgery has recently become a standard therapy. The purpose of the present study was to determine the effectiveness and toxicity of re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy. Methods: We reviewed retrospectively 248 patients treated with (chemo)radiotherapy for oligo-recurrence in lymph nodes from esophageal cancer in five Japanese high-volume centers between 2000 and 2015. Thirty-three patients in whom re-irradiation was performed were enrolled in this study, and the results for patients in whom re-irradiation was performed were compared with the results for other patients. Results: Median maximum lymph node diameter was 22 mm. Median total radiation dose was 60 Gy. The median calculated biological effective dose using the LQ model with α/β = 10 Gy (BED10) in patients in whom re-irradiation was performed was significantly lower than the median BED10 in others. There was no different factor except for BED10, histology and irradiation field between patients with a past irradiation history and patients without a past irradiation history. The median observation period in surviving patients in whom re-irradiation was performed was 21.7 months. The 3-year overall survival rate in the 33 patients with a past irradiation history was 17.9%, with a median survival period of 16.0 months. Overall survival rate and local control rate in patients with a past irradiation history were significantly worse than those in patients without a past irradiation history (log-rank test, p = 0.016 and p = 0.0007, respectively). One patient in whom re-irradiation was performed died from treatment-related gastric hemorrhage. Conclusions: Results in the present study suggested that re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy might be acceptable but unsatisfactory.

KW - Chemoradiotherapy

KW - Esophageal cancer

KW - Oligo-recurrence

KW - Re-irradiation

UR - http://www.scopus.com/inward/record.url?scp=85028891064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028891064&partnerID=8YFLogxK

U2 - 10.1186/s13014-017-0882-0

DO - 10.1186/s13014-017-0882-0

M3 - Article

VL - 12

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 146

ER -